Subcutaneous infliximab CT-P13 Remsima®SC

DRUG2 trials

Sponsors

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Erwin Dreesen

Conditions

IBD - Inflammatory Bowel DiseaseInflammatory Bowel DiseasesRA - Rheumatoid Arthritis

Unknown Phase

A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC

Active, not recruitingNCT04990258

Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesInflammatory Bowel Diseases

Start: 2021-09-06End: 2024-09-30Updated: 2024-01-24

A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease

Not yet recruitingNCT07120152

Erwin DreesenIBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis

Start: 2025-09-01End: 2027-03-01Target: 439Updated: 2025-09-03